United Therapeutics Corporation Stock News

Related Stocks: UTHR ,

By Memorandum Opinion entered by The Honorable Richard G. Andrews in United Therapeutics Corporation v. Liquidia Technologies, Inc., Civil Action No. 20-755-RGA (D.Del. November 18, 2021), the Court issued its claim construction of the two remaining disputed terms of U.S. Patent No. 9,604,901... By: Fox Rothschild LLP

Equities research analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.79 per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for United Therapeutics earnings, with estimates ranging from $3.60 to $3.91. United Therapeutics reported earnings of $2.19 per share in the same quarter last year, []

Bank of America Corp DE lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 25.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,109 shares of the biotechnology companys stock after selling 46,117 shares during the period. Bank of []

LPL Financial LLC raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,406 shares of the biotechnology companys stock after acquiring an additional 108 shares during the quarter. LPL Financial LLCs holdings []

Related Stocks: LNTH , CDNA , SRDX , SIEN , EPIX , NPCE , DICE , UTHR , FLXN , ENTA , ORGO , NRIX , MDXG , RVMD , TKNO , GLTO , PODD , DXCM ,

Related Stocks: UTHR ,

Invesco Ltd. reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 10.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 568,135 shares of the biotechnology companys stock after selling 64,621 shares during the quarter. Invesco Ltd.s holdings in United Therapeutics were worth $101,929,000 at the end of the most recent reporting period. []

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2021 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of 1.48% and 6.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.